Xilio plans to file INDs for its two lead candidates this year. (PDPics/Pixabay)
Xilio Therapeutics has raised $95 million to take IL-2 and CTLA-4 immunotherapies into clinical trials. The series C positions Xilio to provide early clinical validation of anti-cancer agents that are designed to remain inactive until they reach tumors.
Immuno-oncology drugs are typically given systemically, causing them to trigger immune responses that affect healthy and cancerous tissues alike. The resulting adverse events are unpleasant and can prevent physicians from administering the most efficacious dose. Patients suffer from both the side effects and worse outcomes due to the use of suboptimal doses.
The UK government Friday offered the first detailed look at its £800 million disruptive innovation funder, now officially called the Advanced Research and Invention Agency.
The agency, which draws inspiration from the Defense Advanced Research Projects Agency, the US body that has overseen the creation of experimental military technologies, will aim to stimulate new, emerging and high-risk science and technology, the government said in a statement.
Research agency to fund ‘high-risk, high-reward’ science projects
(Lauren Hurley/PA)
A new research agency focusing on areas of science and technology with the potential to generate ground-breaking discoveries has been announced by the Government.
The Advanced Research & Invention Agency (Aria) has received £800 million in funding and will be led by experts who will be given the freedom to identify and fund research involving “high-risk, high-reward” science.
The agency will be independent of government and will look at how to avoid unnecessary bureaucracy, Business Secretary Kwasi Kwarteng said.
Kwasi Kwarteng (Aaron Chown/PA)
He added: “From the steam engine to the latest artificial intelligence technologies, the UK is steeped in scientific discovery.
Health Payment Systems, Inc. Welcomes SV Health Investors as New Lead Investor
Health Payment Systems, Inc. Welcomes SV Health Investors as New Lead Investor
MILWAUKEE, Feb. 11, 2021 /PRNewswire/ Health Payment Systems, Inc. (HPS, the “Company”), an innovator in the healthcare payments space, today announced that SV Health Investors, LLC (“SV”) acquired a majority stake and provided growth financing to the Company. With this transaction, SV adds to its portfolio of growing healthcare technology investments. Hexagon, Inc., a private investment company and one of SV s limited partners, invested in HPS alongside SV.
Since its inception, HPS has helped self-funded employers in the Upper Midwest reduce the cost of healthcare, while maintaining high levels of provider and patient satisfaction. The Company s single-statement billing and patient financing services help families combat confusing and unaffordable medical bills, while its guaranteed payment model eliminates provid
How the UK s Covid-19 vaccines chief bucked the rules to get it to the front of the queue Feb 06, 2021, 09:15 AM
facebook
Kirsty O Connor/PA via Getty Images
Kate Bingham paused her career in venture capital to head up the United Kingdom s Covid-19 vaccine effort.
The UK has leapt ahead in the vaccine race, securing access to 407 million doses of seven types.
Here s the set of high-risk decisions she took to turbo-charge the country s vaccine drive.
Kate Bingham put her role as a life-sciences venture capitalist on hold last July when she was approached by Prime Minister Boris Johnson to head up the UK s Vaccine Taskforce (VTF).